Recursion Pharmaceuticals (RXRX) Competitors $5.53 +0.21 (+3.95%) Closing price 04:00 PM EasternExtended Trading$5.56 +0.03 (+0.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. VRNA, RVMD, MRUS, GRFS, CYTK, CRSP, RYTM, RNA, ABVX, and NUVLShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Grifols (GRFS), Cytokinetics (CYTK), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Its Competitors Verona Pharma PLC American Depositary Share Revolution Medicines Merus Grifols Cytokinetics CRISPR Therapeutics Rhythm Pharmaceuticals Avidity Biosciences Abivax Nuvalent Recursion Pharmaceuticals (NASDAQ:RXRX) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Is RXRX or VRNA more profitable? Verona Pharma PLC American Depositary Share has a net margin of -36.62% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-1,004.91% -76.09% -54.29% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Which has preferable valuation and earnings, RXRX or VRNA? Verona Pharma PLC American Depositary Share has lower revenue, but higher earnings than Recursion Pharmaceuticals. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.84M40.80-$463.66M-$1.78-3.11Verona Pharma PLC American Depositary Share$42.28M217.94-$173.42M-$0.99-107.99 Do insiders and institutionals hold more shares of RXRX or VRNA? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor RXRX or VRNA? In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Verona Pharma PLC American Depositary Share. MarketBeat recorded 16 mentions for Recursion Pharmaceuticals and 12 mentions for Verona Pharma PLC American Depositary Share. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.13 beat Recursion Pharmaceuticals' score of 0.48 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Verona Pharma PLC American Depositary Share 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate RXRX or VRNA? Recursion Pharmaceuticals currently has a consensus price target of $7.25, suggesting a potential upside of 31.10%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, suggesting a potential upside of 1.95%. Given Recursion Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Verona Pharma PLC American Depositary Share 1 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.07 Which has more volatility & risk, RXRX or VRNA? Recursion Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. SummaryRecursion Pharmaceuticals beats Verona Pharma PLC American Depositary Share on 8 of the 15 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.31B$2.61B$6.05B$10.30BDividend YieldN/A57.78%5.73%4.82%P/E Ratio-3.1122.5785.3127.10Price / Sales40.80755.26601.46133.29Price / CashN/A26.3325.7730.18Price / Book2.125.3512.676.69Net Income-$463.66M$33.06M$3.32B$276.55M7 Day PerformanceN/A0.94%-0.44%-1.14%1 Month Performance14.49%9.75%8.72%6.50%1 Year Performance-16.47%-0.52%75.69%33.95% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals2.2651 of 5 stars$5.53+3.9%$7.25+31.1%-19.6%$2.31B$58.84M-3.11400Gap UpVRNAVerona Pharma PLC American Depositary Share1.5547 of 5 stars$106.790.0%$109.00+2.1%N/A$9.21B$42.28M-107.8730Positive NewsRVMDRevolution Medicines4.0771 of 5 stars$46.71+2.2%$74.64+59.8%-4.4%$8.54B$11.58M-10.38250MRUSMerus0.8866 of 5 stars$94.29+0.1%$92.88-1.5%+76.7%$7.12B$36.13M-17.1437GRFSGrifols3.7833 of 5 stars$9.95-0.7%$10.30+3.5%+8.5%$6.89B$7.81B8.5023,822Positive NewsAnalyst DowngradeCYTKCytokinetics3.6483 of 5 stars$56.97+1.2%$75.86+33.2%+9.4%$6.74B$18.47M-11.17250CRSPCRISPR Therapeutics2.0015 of 5 stars$67.74-7.0%$71.50+5.6%+56.0%$6.62B$35M-12.48460Analyst ForecastRYTMRhythm Pharmaceuticals3.3447 of 5 stars$99.02+1.8%$106.64+7.7%+102.4%$6.46B$156.29M-32.90140RNAAvidity Biosciences1.9735 of 5 stars$47.00+6.4%$68.32+45.4%+6.8%$6.45B$10.90M-13.20190ABVXAbivax2.8193 of 5 stars$83.92+1.3%$102.14+21.7%+885.0%$6.26BN/A0.0061Analyst ForecastGap UpNUVLNuvalent2.8635 of 5 stars$84.22+0.4%$118.89+41.2%-15.0%$6.05BN/A-17.1940 Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Competitors Revolution Medicines Competitors Merus Competitors Grifols Competitors Cytokinetics Competitors CRISPR Therapeutics Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Abivax Competitors Nuvalent Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
